Clinical Trials Logo

Clinical Trial Summary

This study is a retrospective real-world study to evaluate the efficacy of Osimertinib for patients with advanced or metastatic EGFR 20exon insertion mutation (20ins) Non-Small Cell Lung Cancer.


Clinical Trial Description

This is a multicenter, retrospective observational real-world study, which evaluates the efficacy of Osimertinib, between 2017 and 2022, in patients with advanced or metastatic EGFR 20exon insertion mutation (20ins) Non-Small Cell Lung Cancer. This study serves as the external control for a single arm phase II trial on JMT101 combined with Osimertinib in patients with Non-Small Cell Lung Cancer. The primary outcome measure is objective response rate (ORR). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05513664
Study type Observational
Source Shanghai JMT-Bio Inc.
Contact Lei Li
Phone 13711344347
Email lclilei@mail.ecspc.com
Status Not yet recruiting
Phase
Start date September 2022
Completion date August 2023

See also
  Status Clinical Trial Phase
Recruiting NCT05048797 - A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations Phase 3
Not yet recruiting NCT05132777 - Efficacy and Safety of JMT101 Combined With Osimertinib in Patients With Non-Small Cell Lung Cancer Phase 2
Recruiting NCT04606446 - Study of PF-07248144 in Advanced or Metastatic Solid Tumors Phase 1
Recruiting NCT05673590 - Utidelone Versus Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Phase 3
Recruiting NCT04686305 - Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC Phase 1
Recruiting NCT04448379 - Efficacy and Safety of JMT101 Combined With Afatinib (or Osimertinib) in Patients With Non-Small Cell Lung Cancer Phase 1
Recruiting NCT05863325 - A Study to Compare the Efficacy and Safety of HB1801 to Taxotere in Advanced Non-Small Cell Lung Cancer (NSCLC) Phase 2
Recruiting NCT04996121 - A Study of XZP-5955 Tablets in Patients With NTRK or ROS1 Fusion Positive Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2